Fortis Memorial Research Institute (FMRI), Gurugram, in partnership with Agilus Diagnostics, has introduced its second Genexus system. The launch is part of an effort to expand what the institutions describe as India’s fastest and most scalable rapid genomic testing programme. The focus is to support timely treatment decisions in oncology through Next-Generation Sequencing (NGS).
The Genexus platform offers NGS-based tests with a shorter turnaround time, including Liquid Biopsy in 24 hours, Myeloid NGS in 72 hours, and MRD (Minimal Residual Disease) testing within five days. Traditional testing methods typically take several weeks, limiting the scope for timely clinical interventions.
Dr Rahul Bhargava, Principal Director and Chief – Haematology and Bone Marrow Transplant at FMRI, said, “With the addition of the second Genexus system, we can now scale our rapid NGS workflow for AML and other hematologic malignancies across more patients and regions. Genomics is not the future anymore – it is the present. Every mutation tells a story. With faster and deeper insights, we’re not only making better treatment decisions but also giving our patients a genuine shot at survival and long-term remission.”
Fortis and Agilus report that the rapid NGS programme has led to measurable improvements in cancer care. With faster test results, patients are starting personalised treatments sooner. According to the institutions, over 40 per cent of patients have received targeted therapies, up from 11 per cent prior to the programme’s implementation.
The programme has also impacted transplant timelines. The average waiting period for bone marrow transplants has been reduced from four months to under three months. Additionally, early mortality rates within the first 30 days of diagnosis have reportedly decreased by more than half. One-year survival rates have increased by 8 per cent for patients who benefited from the rapid diagnostics.
Dr Anand K, MD & CEO of Agilus Diagnostics, stated, “With the second Genexus system in place, we are better positioned to democratise access to advanced molecular diagnostics, delivering not just results, but truly actionable insights in record time. This marks a critical step in bringing personalised medicine closer to every Indian cancer patient.”
The collaboration combines Fortis’ clinical expertise with Agilus’ laboratory infrastructure. It brings together haematologists, oncologists, molecular pathologists, and bioinformaticians under a shared platform aimed at improving access to timely genomic insights.
The post Fortis and Agilus launch second Genexus system to expand rapid genomic cancer testing appeared first on Express Healthcare.
